Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 451 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Progesterone 100 MG Clear all
Completed No phase listed Observational

Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105

NCT00959244
View directory record Official record
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PK of Depo SubQ Injected in the Upper Arm

NCT01143207
View directory record Official record
Conditions
Contraception
Interventions
Medroxyprogesterone acetate
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls

NCT01773772
View directory record Official record
Conditions
Female Puberty
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
9 Years to 14 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 23, 2026, 2:52 PM EDT
Recruiting Phase 4 Interventional

Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

NCT06834594
View directory record Official record
Conditions
Turner Syndrome, Primary Ovarian Insufficiency (Poi)
Interventions
Micronized progesterone 200 MG, Micronized Progesterone 100 MG
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 20 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 2:52 PM EDT
Completed No phase listed Observational

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

NCT00516698
View directory record Official record
Conditions
Breast Cancer
Interventions
polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography
Genetic · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
180
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury

NCT01143064
View directory record Official record
Conditions
Brain Injuries
Interventions
Progesterone, Lipid emulsion without progesterone
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 23, 2026, 2:52 PM EDT
Not listed Not applicable Interventional

Frozen Blastocyst Transfer Using Conventional Timing Versus Timing by Endometrial Receptivity Analysis

NCT03558399
View directory record Official record
Conditions
Implantation Failure, Infertility, Female
Interventions
FET according to ERA, FET according to standard protocol
Other
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PREGNANT Short Cervix Trial

NCT00615550
View directory record Official record
Conditions
Preterm Delivery, Short Cervix, Short Uterine Cervical Length
Interventions
progesterone, placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 23, 2026, 2:52 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
View directory record Official record
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 23, 2026, 2:52 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

NCT01750476
View directory record Official record
Conditions
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions
Mirena, Oral contraception, Depo-Provera
Drug
Lead sponsor
Thomas Cherpes, DVM, MD
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (HOP 5) Testicular Aspiration Addendum

NCT00156650
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 23, 2026, 2:52 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Endometrial Biopsy in Progestin Contraceptive Users

NCT05760144
View directory record Official record
Conditions
Contraception
Interventions
DMPA, Etonogestrel implant
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 23, 2026, 2:52 PM EDT
Terminated Phase 2 Interventional Results available

Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery

NCT01147016
View directory record Official record
Conditions
Breast Cancer
Interventions
HER2Bi-armed activated T cells, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, laboratory biomarker analysis, neoadjuvant therapy, therapeutic conventional surgery
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

NCT02603926
View directory record Official record
Conditions
Fragile X-associated Tremor/Ataxia Syndrome
Interventions
Allopregnanolone
Drug
Lead sponsor
Randi J. Hagerman, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Progesterone Treatment for Cocaine-dependent Women: A Pilot Study

NCT00632099
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Oral micronized progesterone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 23, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

The Role of Estrogen in the Neurobiology of Eating Disorders

NCT03740204
View directory record Official record
Conditions
Eating Disorders, Hypoestrogenemia
Interventions
17-β estradiol transdermal patches with cyclic progesterone, Placebo patch and pill
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 35 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 23, 2026, 2:52 PM EDT
Terminated Not applicable Interventional Results available

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

NCT01428193
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism
Interventions
Flutamide, Progesterone, estrace
Drug
Lead sponsor
University of Virginia
Other
Eligibility
13 Years to 17 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 23, 2026, 2:52 PM EDT
Recruiting Phase 4 Interventional

Estrogen Supplementation and Bone Health in Women With CF

NCT05704036
View directory record Official record
Conditions
Cystic Fibrosis, Hypoestrogenism
Interventions
Transdermal estrogen, Progesterone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 100 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

NCT00365599
View directory record Official record
Conditions
Breast Cancer
Interventions
suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
8
States / cities
San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 23, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Impact of Contraception on Postpartum Weight Loss

NCT02144259
View directory record Official record
Conditions
Weight
Interventions
DMPA immediately postpartum, Implanon immediately postpartum
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 23, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

NCT00702702
View directory record Official record
Conditions
Uterine Fibroids, Anemia
Interventions
Proellex 25 mg, Proellex 50 mg, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 23, 2026, 2:52 PM EDT
Not listed Phase 2 Interventional

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

NCT01800422
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
telapristone acetate, placebo, therapeutic conventional surgery, laboratory biomarker analysis, questionnaire administration
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 23, 2026, 2:52 PM EDT